Jazz Pharmaceuticals Plc Forecast, price target & analysts
Jazz Pharmaceuticals Plc Target price 2026 - Analyst rating & recommendation
Jazz Pharmaceuticals Plc Classifications & Recommendation
Jazz Pharmaceuticals Plc Price Target
| Target Price | $306.00 |
| Price | $237.95 |
| Potential |
28.60%
register free of charge
|
| Number of Estimates | 22 |
|
22 Analysts have issued a price target Jazz Pharmaceuticals Plc 2027 .
The average Jazz Pharmaceuticals Plc target price is $306.00.
This is
28.60%
register free of charge
$338.10
42.09%
register free of charge
$200.66
15.67%
register free of charge
|
|
| A rating was issued by 26 analysts: 24 Analysts recommend Jazz Pharmaceuticals Plc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Jazz Pharmaceuticals Plc stock has an average upside potential 2027 of
28.60%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Billion $ | 4.27 | 4.81 |
| 4.88% | 12.66% | |
| EBITDA Margin | 27.47% | 49.44% |
| 17.45% | 79.98% | |
| Net Margin | -8.35% | 34.44% |
| 160.62% | 512.68% |
23 Analysts have issued a sales forecast Jazz Pharmaceuticals Plc 2026 . The average Jazz Pharmaceuticals Plc sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Jazz Pharmaceuticals Plc EBITDA forecast 2026. The average Jazz Pharmaceuticals Plc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
23 Jazz Pharmaceuticals Plc Analysts have issued a net profit forecast 2026. The average Jazz Pharmaceuticals Plc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -5.84 | 25.55 |
| 168.87% | 537.50% | |
| P/E | 9.31 | |
| EV/Sales | 3.66 |
23 Analysts have issued a Jazz Pharmaceuticals Plc forecast for earnings per share. The average Jazz Pharmaceuticals Plc EPS is
This results in the following potential growth metrics and future valuations:
Jazz Pharmaceuticals Plc...
Current Jazz Pharmaceuticals Plc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Sep 24 2026 |
| UBS |
Locked
➜
Locked
|
Locked | Sep 11 2026 |
| Barclays |
Locked
➜
Locked
|
Locked | Sep 10 2026 |
| Deutsche Bank |
Locked
➜
Locked
|
Locked | Aug 26 2026 |
| Truist Securities |
Locked
➜
Locked
|
Locked | Aug 26 2026 |
| Morgan Stanley |
Locked
➜
Locked
|
Locked | Aug 26 2026 |
| Needham |
Locked
➜
Locked
|
Locked | Aug 26 2026 |
| Analyst Rating | Date |
|---|---|
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Sep 24 2026 |
|
Locked
UBS:
Locked
➜
Locked
|
Sep 11 2026 |
|
Locked
Barclays:
Locked
➜
Locked
|
Sep 10 2026 |
|
Locked
Deutsche Bank:
Locked
➜
Locked
|
Aug 26 2026 |
|
Locked
Truist Securities:
Locked
➜
Locked
|
Aug 26 2026 |
|
Locked
Morgan Stanley:
Locked
➜
Locked
|
Aug 26 2026 |
|
Locked
Needham:
Locked
➜
Locked
|
Aug 26 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
